Advanced search×

In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.

In Vivo 25(1):55-9 (2011) PMID 21282735

The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model.

Version: za2963e q8za9 q8zbc q8zcf q8zd3 q8ze3 q8zfc q8zgc

Similar articles you may find interesting…

  1. Multistep Targeted Nano Drug Delivery System Aiming at Leukemic Stem Cells and Minimal Residual Disease.

    Mol Pharm (2013) PMID 23646913

    Refractory leukemia remains the most common therapeutic problem in clinical treatment of leukemia. The key therapy of refractory leukemia is to kill, thoroughly, the minimal residual disease and leukemia stem cells in the highly vascularized red marrow areas. In this study, two new c...
  2. Gold-Nanobeacons for gene therapy: evaluation of genotoxicity, cell toxicity and proteome profiling analysis.

    Nanotoxicology (2013) PMID 23642008

    We constructed an Antisense Gold-nanobeacon consisting of a stem-looped oligonucleotide double labeled with 3'-Cy3 and 5'-Thiol-C6 and tested for the effective blocking gene expression in colorectal cancer cells. Due to the beacon conformation, gene silencing was directly detected as fluorescence in...
  3. Microbiological Quality and Characteristics of Probiotic Products in China.

    J Sci Food Agric (2013) PMID 23653326

    Twenty commercial dairy products and eight commercial "health-care" samples were collected from markets in China, and were tested using culture-dependent and -independent methods. Results suggested that the total bacterial counts of most commercial products could meet the minimum quantitative requir...